Scancell Holdings Plc · LSE:SCLP
Scancell — Shareholder Meeting (October 2016)
17 slides from Scancell's shareholder meeting presentation, Oct 18, 2016
Slide 1: A New Frontier in T-Cell Activation and Targeting
A NEW FRONTIER IN T-CELL ACTIVATION AND TARGETING AGM PRESENTATION 18 Oct 2016 Dr John Chiplin: Executive Chairman Dr Richard Goodfellow: CEO Professor Lindy Durrant: CSO LSE AIM Symbol: SCLP.L A NEW FRONTIER IN T-CELL ACTIVATION AND TARGETING
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT Today’s presentation includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding our planned pre-clinical stu
Slide 3: Scancell Immuno-Oncology
SCANCELL IMMUNO-ONCOLOGY TWO PLATFORMS IMMUNOBODY® - Potent innovative DNA-based immunotherapy platform for the generation of ultra-high avidity anti-tumor T-cells MODITOPE® - Citrullinated peptides that deliver potent killer helper T cells during autophagy THREE PRODUCTS SCIB1, SCIB2, Modi-1 FI
Slide 4: Drug Pipeline
DRUG PIPELINE LEAD CANDIDATES IMMUNOBODY® SCIB1: Targets malignant melanoma. Phase 1/2 study completed with promising results. Phase 2b combination trial with immune checkpoint inhibitor planned for Q3 2017. IMMUNOBODY® SCIB2: Targets non-small cell lung cancer (NSCLC). Phase 1/2, combination trial
Slide 5: The ImmunoBody Platform
THE IMMUNOBODY® PLATFORM MEETING THE NEED FOR AN EFFECTIVE THERAPEUTIC CANCER VACCINE Successes in the cancer vaccine space include preventative anti-viral vaccines such as Gardasil®, 1 Cervarix®, and Recombivax HB® and therapeutic vaccines such as Provenge® and Imlygic® Therapeutic anti-cancer vacc
Slide 6: Survival "Well Beyond Established Norms"
PROMISING PHASE 1/2 TRIAL RESULTS IN MELANOMA PATIENTS SURVIVAL “WELL BEYOND ESTABLISHED NORMS”* Of the 20 patients with resected stage III and IV melanoma enrolled in the trial, 95% remain alive today (16 enrolled 2011-2013; 4 enrolled 2014-2015) Overall survival (OS) or recurrence-free surviva
Slide 7: Survival "Well Beyond Established Norms"
RESULTS OF PHASE 1/2 TRIAL RESULTS IN MELANOMA PATIENTS SURVIVAL “WELL BEYOND ESTABLISHED NORMS”* Median observation time since trial entry is 4 years for 16 patients with resected tumors and receiving 2–4 mg doses Only five patients had disease recurrence and one died Median observation time
Slide 8: ImmunoBody Clinical Development Plans
IMMUNOBODY® CLINICAL DEVELOPMENT PLANS UPCOMING CLINICAL TRIALS PHASE 2b COMBINATION STUDY PHASE 1/2 COMBINATION STUDY SCIB1 + Anti-PD-1 immune checkpoint SCIB2 + Anti-PD-1 immune checkpoint inhibitor in melanoma inhibitor in non-small cell lung cancer RATIONALE FOR THE SCIB1 PHASE 2b COMBINATION TR
Slide 9: ImmunoBody Clinical Development Plans
IMMUNOBODY® CLINICAL DEVELOPMENT PLANS DESIGN FEATURES OF THE SCIB1 PHASE 2b COMBINATION TRIAL Stage 1 Stage 2 Safety Run-In 21 18 Melanoma patients with 6 Pembrolizumab advanced metastatic alone disease 21 18 SCIB1 8 mg Pembrolizumab 2 mg/kg Pembrolizumab + SCIB1 For each group ≥9 RECIST Considered
Slide 10: ImmunoBody Clinical Development Plans
IMMUNOBODY® CLINICAL DEVELOPMENT PLANS RATIONALE FOR THE SCIB2 PHASE 1/2 COMBINATION TRIAL FOR LUNG CANCER 80% of patients with non-small cell lung cancer (NSCLC) fail to respond to anti-PD-1 inhibitors because their tumours are insufficiently immunogenic Therapeutic cancer vaccination and T-cel
Slide 11: ImmunoBody Clinical Development Plans
IMMUNOBODY® CLINICAL DEVELOPMENT PLANS DESIGN OF THE SCIB2 PHASE 1/2 COMBINATION TRIAL IN NSCLC Dose Escalation Stage 1 Stage 2 15 13 18 NY-ESO-1 positive PD-1 mAb alone NSCLC patients 15 13 3x3 SCIB2 escalation PD-1 mAb + SCIB2 then comb w/PD-1 mAb at labelled dose and schedule ≥3 RECIST responses
Slide 12: The Commercial Landscape
THE COMMERCIAL LANDSCAPE MARKET OPPORTUNITIES FOR SCIB1/SCIB1 PLUS COMBINATION WITH CHECKPOINT INHIBITORS IN METASTATIC SETTING Stage III/IV patients are indicated for checkpoint inhibitor therapy There are a growing number of available patients as approved use broadens to include larger segment
Slide 13: The Moditope Platform
THE MODITOPE® PLATFORM A NOVEL IMMUNOTHERAPY THAT OVERCOMES IMMUNOSUPPRESSION AND DELIVERS UNPRECEDENTED KILLER T-HELPER CELL RESPONSES Post-translational modifications of proteins occur under conditions of cellular stress One such modification involves the process of citrullination Involves t
Slide 14: The Moditope Platform
THE MODITOPE® PLATFORM CITRULLINATED PEPTIDES (MODITOPE®) ACTIVATE KILLER T-HELPER CELLS THAT SEEK AND DESTROY CANCER CELLS - update Identified new targets Optimized formulation (reduced dose by 100 fold) Identified a new modification Showed worked in 3 other mouse models (ID8- ovarian cance
Slide 15: Lead Moditope Candidate Modi-1
THE MODITOPE® PLATFORM LEAD MODITOPE® CANDIDATE MODI-1 Consists of: Two citrullinated vimentin peptides (Vim-1 and Vim-2) One citrullinated enolase peptide (Eno-1) Vimentin and enolase targets are highly expressed in triple negative breast cancer (90%), ovarian cancer (95%), and osteosarcoma
Slide 16: The Moditope Clinical Development Plan
THE MODITOPE® CLINICAL DEVELOPMENT PLAN DESIGN OF THE MODI-1 PHASE 1/2 TRIAL Stage 1 Stage 2 Dose Escalation 15 10 Cancer Type 1 10 Modi-1 alone ‘vaccine’ 15 10 esc. design Cancer Type 2 Modi-1 alone Modi-1 dose escalation 15 10 Cancer Type 3 Modi-1 alone Patient Selection ≥2 RECIST responses Consid
Slide 17: Anticipated News Flow: 2016-2018
ANTICIPATED NEWS FLOW: 2016-2018 2016 Q4 SCIB1 phase 1/2 final Clinical Report completed SCIB1 phase 1/2 survival update Start Modi-1 manufacture 2017 2018 Q1 Q1 SCIB1 IND filed Safety data on SCIB1/checkpoint inhibitor combination released Q2 SCIB1 IND approval First patient treated in Modi-1 trial
Scancell Holdings — Shareholder Meeting (October 2016) on 6ix